Institutional shares held 82.8 Million
680K calls
896K puts
Total value of holdings $213M
$1.75M calls
$2.3M puts
Market Cap $212M
82,305,696 Shares Out.
Institutional ownership 100.63%
# of Institutions 234


Latest Institutional Activity in RVNC

Top Purchases

Q3 2024
Fil LTD Shares Held: 4.19M ($10.8M)
Q3 2024
Alpine Associates Management Inc. Shares Held: 4.16M ($10.7M)
Q3 2024
Alliancebernstein L.P. Shares Held: 3.26M ($8.38M)
Q3 2024
Magnetar Financial LLC Shares Held: 2.5M ($6.43M)
Q3 2024
Water Island Capital LLC Shares Held: 2.38M ($6.12M)

Top Sells

Q3 2024
Palo Alto Investors LP Shares Held: 1.61M ($4.14M)
Q3 2024
Jpmorgan Chase & CO Shares Held: 134K ($345K)
Q3 2024
Federated Hermes, Inc. Shares Held: 9 ($23.1)
Q3 2024
Stonepine Capital Management, LLC Shares Held: 820K ($2.11M)
Q3 2024
Franklin Resources Inc Shares Held: 4.78M ($12.3M)

About RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.


Insider Transactions at RVNC

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
450K Shares
From 12 Insiders
Grant, award, or other acquisition 420K shares
Open market or private purchase 30K shares
Sell / Disposition
63.6K Shares
From 9 Insiders
Payment of exercise price or tax liability 30.6K shares
Open market or private sale 33K shares

Track Institutional and Insider Activities on RVNC

Follow Revance Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC